Literature DB >> 31450490

PCDH20 acts as a tumour-suppressor gene through the Wnt/β-catenin signalling pathway in hypopharyngeal squamous cell carcinoma.

Zhitao Gong, Guohua Hu.   

Abstract

BACKGROUND: Downregulation of PCDH20 is frequently involved in tumorigenesis of many cancers, but the role of PCDH20 protein in hypopharyngeal squamous cell carcinoma (HSCC) is still unknown.
OBJECTIVE: The aim of this study was to investigate the role of PCDH20 in hypopharyngeal squamous cell carcinoma (HSCC).
METHODS: Immunohistochemistry (IHC) and qRT-PCR was carried out to estimate the expressions of PCDH20 protein and mRNA in HSCC tissues and adjacent non-tumor tissues. Correlation between the PCDH20 expression and clinicopathological characteristics was evaluated using chi-square test. Meanwhile, Kaplan-Meier method and log-rank test were applied to analyze the overall survival. After transfection of PCDH20, the CCK8 assay, Cell migration assay and invasion assay were used to investigate the changes in the viability, migration and invasion of Fuda cells. The mechanisms by which reduced PCDH20 promote migration and invasion of Fuda cells were examined using western blotting.
RESULTS: PCDH20 protein showed in tumor tissue low expression rates of 67.5% (54/80). The mRNA of PCDH20 indicated the consistent trend (80%, 8/10). Reduced PCDH20 expression was positively related to T stage and lymph node metastasis (P< 0.05). Patients with low levels of PCDH20 had worse overall survival compared with those with high PCDH20 levels (P< 0.001). The univariate Cox regression analysis described that lymph node metastasis (P= 0.043) and down-regulated PCDH20 expression (P= 0.045) were significantly prognostic factors.Multivariate analysis suggested that low PCDH20 expression (P= 0.015) were significantly independent prognostic factors for overall survival. PCDH20 in Fadu cells significantly inhibited cell viability, migration and invasion. Meanwhile, PCDH20 was involved in the disruption of HSCC progression through antagonizing its downstream Wnt/β-catenin signalling pathway.
CONCLUSION: Our data highlight that the downregulated PCDH20 may serve as reliable diagnostic biomarker in HSCC.

Entities:  

Keywords:  PCDH20; clinicopathological features; hypopharyngeal squamous cell carcinoma; lymph node metastasis; prognostic

Mesh:

Substances:

Year:  2019        PMID: 31450490     DOI: 10.3233/CBM-190442

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  5 in total

1.  Suppression of Long Noncoding RNA SNHG1 Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma via Increasing PARP6 Expression.

Authors:  Qian Chen; Xiao He; Bin Li; Jingjing Chen; Xuxia Tang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-05       Impact factor: 2.650

2.  TTC36 inactivation induce malignant properties via Wnt-β-catenin pathway in gastric carcinoma.

Authors:  Lei Song; Xiaonong Guo; Fei Zhao; Wei Wang; Zhifang Zhao; Long Jin; Chengli Wu; Jibin Yao; Zhongren Ma
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

3.  PCDH20 inhibits esophageal squamous cell carcinoma proliferation and migration by suppression of the mitogen-activated protein kinase 9/AKT/β-catenin pathway.

Authors:  Yijiao Ning; Chaoqun Deng; Chunhong Li; Weiyan Peng; Chun Yan; Jing Ran; Weihong Chen; Yujia Liu; Jiuyi Xia; Lin Ye; Zhengqiang Wei; Tingxiu Xiang
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

4.  Molecular Markers of MDR of Chemotherapy for HSCC: Proteomic Screening With High-Throughput Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Bin Shen; Xuelin Dong; Bo Yuan; Zhijun Zhang
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

5.  Metformin Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma through Circ_0003214-Mediated MiR-489-3p-ADAM10 Pathway.

Authors:  Xiaoqiang Chen; Chen Li; Wei Chen; Shuchun Lin; Xuehan Yi; Qin Lin; Hao Xu; Desheng Wang
Journal:  J Oncol       Date:  2021-07-13       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.